The objective of this Phase III study is to evaluate the efficacy of nintedanib in patients with metastatic colorectal cancer (mCRC) after failure of previous treatment with standard chemotherapy and biological agents.

Elegibilidad

Edad mínima: 18 YearsSexo: ALL

Criterios de inclusión

\- cetuximab or panitumumab for patients with K-Ras wt or Ras wt tumours
\- fluoropyrimidine
\- oxaliplatin: Patients treated with oxaliplatin in adjuvant setting should have progressed within 6 months of completion of adjuvant therapy or they must have been treated with oxaliplatin for metastatic disease
\- irinotecan
\- bevacizumab or aflibercept
Age \>= 18 years
Signed informed consent
Histologically or cytologically confirmed colorectal adenocarcinoma
Metastatic or locally advanced disease not amenable to curative surgery and/or radiotherapy
Eastern Cooperative Oncology Group (ECOG) performance status = 1
At least one measurable lesion according to Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1
Progression on standard therapies or withdrawn from standard treatment due to unacceptable toxicity. Previous standard treatment must include all of the following:
\- The remaining standard available therapy as recommended by investigator is best supportive care (note: previous treatment with regorafenib and TAS 102 are allowed and these agents should be administered before study if available to patient according to local standards)
\- Life expectancy of at least 12 weeks
\- Hepatic function: aspartate aminotransferase (AST)/ Alanine Amino Transferase (ALT) = 1.5 X Upper Limit of Normal (ULN) and bilirubin = ULN for patients without liver metastases. AST/ALT = 2.5 X ULN and bilirubin = ULN for patients with liver metastases. Patients with Gilbert syndrome and bilirubin \< 2 X ULN and normal AST/ALT are eligible
Coagulation parameters: International normalised ratio (INR) \< 2 and partial prothrombin Time (PTT) = 2xULN

Criterios de exclusión

Previous treatment with nintedanib
toxicity attributed to previous anticancer therapy that did not resolve to Common Terminology Criteria for Adverse Events (CTCAE) grade =1
History of other malignancies in the last 5 years, in particular those that could interfere with interpretation of results.
Serious concomitant disease or medical condition affecting compliance with trial requirements or which are considered relevant for the evaluation of the efficacy or safety of the trial drug,
Significant cardiovascular diseases
History of severe haemorrhagic or thromboembolic event in the past 12 months
Bleeding or thrombotic disorders requiring anticoagulant therapy such as warfarin, or similar agents requiring therapeutic INR monitoring
Gastrointestinal disorders or abnormalities that would interfere with absorption of study drug
Patient with brain metastases that are symptomatic and/or require therapy.
Patients of childbearing potential who are sexually active and unwilling to use a highly effective method of contraception
Pregnancy or breast-feeding.

Ubicaciones

1199.52.5404 Boehringer Ingelheim Investigational Site

Cdad. de Córdoba, Argentina

1199.52.5405 Boehringer Ingelheim Investigational Site

Cdad. de Córdoba, Argentina

1199.52.5401 Boehringer Ingelheim Investigational Site

Ciudad Autónoma de Bs As, Argentina

1199.52.5403 Boehringer Ingelheim Investigational Site

Ciudad Autónoma de Bs As, Argentina

1199.52.5406 Boehringer Ingelheim Investigational Site

Ciudad Autónoma de Bs As, Argentina

A Double-blind, Randomised, Placebo Controlled Phase III Study of Nintedanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Therapies.

Resumen

Elegibilidad

Criterios de inclusión

Criterios de exclusión

Intervenciones

Nintedanib (BIBF 1120)

Placebo

BSC

BSC

Ubicaciones

1199.52.5404 Boehringer Ingelheim Investigational Site

1199.52.5405 Boehringer Ingelheim Investigational Site

1199.52.5401 Boehringer Ingelheim Investigational Site

1199.52.5403 Boehringer Ingelheim Investigational Site

1199.52.5406 Boehringer Ingelheim Investigational Site

Patrocinadores